SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03055169

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure

This study evaluates the link between genetic polymorphisms as r7903146, rs12255372 of TCF7L2 gene and the risk of developing hyperglycemia during Intensive care unit stay

NCT03055169 Genetic Predisposition to Disease Hyperglycemia Intensive Care Unit Syndrome Multiple Organ Failure
MeSH: Hyperglycemia Disease Susceptibility Genetic Predisposition to Disease Multiple Organ Failure
HPO: Hyperglycemia Postprandial hyperglycemia

2 Interventions

Name: genetic analysis

Type: Genetic

intensive care patients

Name: blood and stools samples

Type: Biological

intensive care patients


Primary Outcomes

Description: find a link between genetic polymorphism of TCF7L2 and the risk of developing hyperglycemia in intensive care patients with a least one organ dysfunction. the hyperglycemia is defined fasting glucose> 1.26 g / l twice or need for treatment with insulin)

Measure: value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of hyperglycemia

Time: one year after inclusion

Secondary Outcomes

Measure: Changes in inflammatory markers

Time: one year after inclusion

Description: Changes in cholesterol total, LDL cholesterol, HDL cholesterol and triglycerides

Measure: Changes in serum lipid profile

Time: one year after inclusion

Description: Changes in total alanine transaminase (ALT) total gamma-GT total aspartate transaminase (AST)

Measure: Changes in liver enzymes

Time: one year after inclusion

Description: Calculated using the updated homeostasis model assessment (HOMA) calculator.Higher numbers indicate higher insulin resistance. There are no established cutoffs indicating impaired resistance.

Measure: Insulin Resistance (HOMA)

Time: one year after inclusion

Other Outcomes

Description: the blood samples collection will created for next research Both on diabetes and / or insulin resistance as its determinisms, at the ICU patient

Measure: Blood samples collection

Time: 5 years

Description: the prevalence of TCF7L2, in the intensive care patient or not glycemic control, and compared to the values found in the general population. the TCF7L2 genes will be evaluated by the Taqman method (7900HT Fast Real-Time PCR System-Applied BioSystem).

Measure: Number of patients with genotype TCF7L2 by PCR

Time: 5 years

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 rs12255372

TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure This study evaluates the link between genetic polymorphisms as r7903146, rs12255372 of TCF7L2 gene and the risk of developing hyperglycemia during Intensive care unit stay value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of hyperglycemia.



HPO Nodes


HPO:
Hyperglycemia
Genes 66
BLK CACNA1S CACNA1S KCNJ11 IL6 KCNJ11 CEL HNF1A INSR SHPK STAT3 GYS2 INS ZFP57 PTF1A ABCC8 ABCC8 INS LMNA PDX1 ABCC8 KCNJ11 INS GCK INS KCNE3 ZMPSTE24 INSR HYMAI HNF4A ABCC8 GCK INS ITPR3 ZFP57 PLAGL1 KCNJ11 SCN4A APPL1 HNF1A NEUROD1 ABCC8 ACAT1 PPARG GCK RFX6 PAX4 HNF1A ARMC5 GYS2 GABRA3 LMNA PDX1 PTPN22 KCNJ11 GATA6 LMNA GLI3 LRPPRC HYMAI KCNJ18 KLF11 EIF2AK3 KCNJ11 PDX1 PIK3R1
Postprandial hyperglycemia
Genes 11
GABRA3 SCN4A KCNE3 CACNA1S CACNA1S KCNJ18 INSR INSR SHPK GYS2 GYS2